Association between body weight and tocilizumab effectiveness in rheumatoid arthritis: results from the BSRBR-RA.

ABSTRACT:

Objectives

Tocilizumab is an IL-6 receptor humanized monoclonal antibody for the treatment of rheumatoid arthritis (RA) with intravenous (IV) and subcutaneous (SC) preparations available. Only IV tocilizumab is dosed adjusting for weight. Therefore, we aimed to study the association between body weight and the effectiveness of tocilizumab by the route of administration.

Methods

Patients with RA-administered tocilizumab in the BSRBR-RA were included in the analysis and stratified by route of administration. Outcomes included the 6-month change in DAS28, the proportion of patients achieving DAS28 remission, 6-month EULAR response and persistence of the first route of tocilizumab administration. The exposure was every increase in 10 kg of body weight. Adjusted regression models

SUBMITTER: Tsoi MF 

PROVIDER: S-EPMC11781575 | biostudies-literature | 2025 Feb

REPOSITORIES: biostudies-literature